QureBio Ltd., a clinical-stage biopharmaceutical company focusing on 
bi-specific antibodies and other engineered bio-therapeutics for the treatment 
of cancer, inflammation, and other serious disorders, today announced that its 
Q-1802 clinical program was selected for presentation at American Society of 
Clinical Oncology (ASCO) Annual Meetings on June 3–7, 2022, and the abstract of 
relevant results for this study has been published on ASCO website 
(https://meetings.asco.org/abstracts-presentations/210075).

The presentation will showcase the preliminary results of a first-in-human 
Phase 1a/1b, multicenter, open-label oncology study designed to evaluate the 
safety and anti-cancer activity Q-1802, a Claudin18.2/PD-L1 bi-specific 
therapeutic in patients with relapsed or refractory solid tumors after standard 
therapies. Professor Lin Shen from Peking University Cancer Hospital and 
Institute leads this study. The key data from the mono-therapy of Q-1802 in 
both dose-escalation and dose-expansion studies demonstrate excellent safety, 
tolerability, and preliminary anti-tumor activities of Q-1802 at the dose up to 
10 mpk.

The abstract for the study is found in 2022-ASCO-Annual –Meeting Abstracts 
(#2568), and the poster session information is listed below. First Author, Dr. 
Jifang Gong from the Department of Gastrointestinal Oncology, Peking University 
Cancer Hospital and Institute will present the relevant results on Sunday, June 
5, 2022.

Session Title: Developmental Therapeutics—Immunotherapy
Session Type: Poster Session
Date: Sunday, June 5, 2022
Time: 8:00 AM - 11:00 AM,                         Chicago Time (CDT)

Location: Hall A
Abstract ID (Temp. ID): 2568 (368426)
Poster Board #: 223
Role Responsibilities: Presenter
Primary Track: Developmental Therapeutics—Immunotherapy

Session begins on Jun 5, 2022 at 8:00 AM          Chicago Time (CDT)
Room:                 Hall A-14355
Persons:             Dr. Jifang Gong
Presenting from 8:00 AM - 11:00 AM,               Chicago Time (CDT)

About Q-1802

Q-1802, a humanized bi-specific antibody, is the first FDA-approved 
Claudin18.2/PD-L1 bi-specific therapeutic to enter clinical trial. In animal 
model studies, Q-1802 demonstrates both superior anti-tumor activities and 
excellent safety profiles. It recruits multiple immune mechanisms to kill tumor 
cells, offering a novel therapeutic opportunity for Claudin18.2 positive solid 
tumors. Q-1802 also exhibits robust physicochemical properties and superb 
productivity with titers exceeding 4 grams per liter.

About QureBio Ltd.

QureBio Ltd. is a clinical-stage biopharmaceutical company focusing on 
innovative biopharmaceuticals for urgent and unmet clinical needs, such as the 
treatment of refractory cancers, inflammation and other serious disorders. 
Founded by experienced scientists from the relevant fields, QureBio Ltd. has 
built up a series of proprietary technologies for engineered 
bio-macromolecules, including innovative platforms for bi-specific and 
tri-specific antibodies.

Founded in 2017 with seed capital from Viva Bio-Innovator, QureBio Ltd. has 
since received a series of funds from Jundu Investment, Watson Capital, 
Shenzhen Capital Group, New value Capital,  Bocom Industrial Investment 
(Hangzhou) Equity Investment Partnership, Suzhou Oriza Holdings, Hangzhou 
CAPITAL GuoShun, Zhuhai Longmen Capital Management, Shanghai Pudong Kechuang 
Group, Shenzhen Lihe Hongxin Venture and Three Rivers Capital. QureBio Ltd. has 
secured a Series-B funding of nearly 200 million CNY.

QureBio Ltd. engages in collaboration with partners to develop novel 
therapeutics for unmet medical needs and has on-going cooperation with a series 
of industrial partners including BRL Medicine, BioMap, Precision Scientific, 
and Hengrui Pharmaceuticals, an industry leader in China.

Source: QureBio Ltd.